FDA accepts BLA resubmission of pz-cel in recessive dystrophic epidermolysis bullosa and sets PDUFA target action date of April 29, 2025 Company makes significant progress toward potential commerciali ...

FDA accepts BLA resubmission of pz-cel in recessive dystrophic epidermolysis bullosa and sets PDUFA target action date of April 29, 2025Company ...

Celebrating a Liverpool Legend’s Contributions to Football and CharityLiverpool’s Graeme Souness, an iconic figure in British ...

For years, he has been an active vice president of DEBRA UK, a charity devoted to supporting those affected by Epidermolysis ...

FDA allows for continued dosing of subjects in Phase 1 trial of ZKN-013 Following successful dosing of the initial subjects, FDA has allowed continued dosing of healthy volunteers for ZKN-013 for the ...

The Food and Drug Administration (FDA) has accepted for review the resubmitted Biologics License Application (BLA) for prademagene zamikeracel for the treatment of recessive dystrophic epidermolysis ...

Graeme Souness has been made a CBE for his services to football and charity. The former Rangers and Liverpool star said ...

The football star is the vice president of Debra UK which raises awareness of epidermolysis bullosa, a group of genetic skin ...

Discover six exosome therapy companies developing these tiny extracellular vesicles to treat an array of diseases.

About prademagene zamikeracel (pz-cel) Prademagene zamikeracel (pz-cel), Abeona’s investigational autologous, COL7A1 gene therapy, is currently being developed for the treatment of recessive ...

12-year-old Casey Connors is a sixth class student in Clondalkin, and suffers from the most severe form of Epidermolysis Bullosa, otherwise known as Butterfly Skin, which can cause extensive ...